Efficacy News and Research

RSS

Aethic, King's College London to develop first sunscreen based on mycosporine-like amino acids

King's College London has entered into an agreement with skincare company Aethic to develop the first sunscreen based on MAA's (mycosporine-like amino acids), produced by coral.

12 Sep 2012

HSS receives NFL grant for research into platelet-rich plasma and stem cells

Researchers at Hospital for Special Surgery have been awarded a $100,000 grant from the National Football League (NFL) Charities to research the use of platelet-rich plasma (PRP) and stem cells as treatments for tendon injury and degeneration. For years, PRP has been used to improve healing in various sports injuries, but there is little evidence of its efficacy.

12 Sep 2012

Positive results from Santarus rifamycin SV MMX Phase III study on travelers' diarrhea

Santarus, Inc. today announced that its Phase III clinical study to evaluate the safety and efficacy of the investigational drug, rifamycin SV MMX, met the primary endpoint of reducing time to last unformed stool (TLUS) in patients with travelers' diarrhea.

12 Sep 2012

Minimally invasive esophagectomy viable alternative to open surgery

Patients undergoing surgery for esophageal cancer may benefit from minimally invasive techniques as much as they do from open surgery, say researchers.

11 Sep 2012

Dengue vaccine breakthrough

Results of the first ever trial to show that a safe and effective dengue vaccine may be possible are published Online First in The Lancet.

11 Sep 2012

Pergamum initiates LL-37 Phase I/II trial in hard-to-heal venous leg ulcers

Pergamum AB announced today that dosing has begun in a randomized Phase I/II trial of LL-37 for the treatment of patients with hard-to-heal venous leg ulcers.

11 Sep 2012

Cell Therapeutics launches Pixuvri in the European Union

Cell Therapeutics, Inc., a company focused on translating science into novel cancer therapies, today announced the initiation of the commercial launch of Pixuvri in the European Union with entry into Sweden, Denmark and Finland in September, to be followed by Austria and Norway in early October 2012 and Germany, United Kingdom and the Netherlands in November 2012.

11 Sep 2012

Oxyphenbutazone can kill drug resistant TB

An off-patent anti-inflammatory drug that costs around two cents for a daily dose in developing countries has been found by researchers at Weill Cornell Medical College to kill both replicating and non-replicating drug resistant tuberculosis in the laboratory -- a feat few currently approved TB drugs can do, and resistance to those is spreading.

11 Sep 2012

Palatin Technologies completes bremelanotide Phase 2B trial on female sexual dysfunction

Palatin Technologies, Inc. today announced that the last patient has completed treatment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD).

11 Sep 2012

Florida Hospital Tampa adopts FDA approved Trevo Pro Clot Retriever

Florida Hospital Tampa and Dr. James E. Lefler are the first in the Tampa Bay area to adopt the new FDA approved device called the Trevo Pro Clot Retriever manufactured by Stryker. The Trevo Pro is the next generation in clot removal technology.

10 Sep 2012

HIV viruses with two genetic 'footprints' associated with greater vaccine efficacy

Scientists used genetic sequencing to discover new evidence that the first vaccine shown to prevent HIV infection in people also affected the viruses in those who did become infected. Viruses with two genetic "footprints" were associated with greater vaccine efficacy. The results were published today in the online edition of the journal Nature.

10 Sep 2012

Islet Sciences licenses noninvasive technology from Winthrop for detecting Beta cell death

Islet Sciences, Inc., a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced that it has exclusively licensed technology from Winthrop University Hospital. This technology is complimentary to the early Beta cell destruction diagnostic that Islet Sciences licensed last month.

10 Sep 2012

Increased use of powerful antipsychotic drugs to treat publicly insured children

A national study conducted by researchers at The Children's Hospital of Philadelphia (CHOP) shows increased use of powerful antipsychotic drugs to treat publicly insured children over the last decade. The study, published today in the journal Health Services Research, found a 62 percent increase in the number of Medicaid-enrolled children ages 3 to 18 taking antipsychotics, reaching a total of 354,000 children by 2007.

10 Sep 2012

Atox Bio AB103 for Necrotizing Soft Tissue Infections granted FDA Fast Track designation

Atox Bio, a clinical stage biotechnology company engaged in the development of novel immunemodulators for severe infections in critically ill patients, announced today that the U.S. Food and Drug Administration has granted Fast Track designation to AB103, its lead product, currently in development for the treatment of Necrotizing Soft Tissue Infections (NSTI).

10 Sep 2012

Phase III data for Suvorexant, an investigational insomnia medicine, announced

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. The new data are from one of the longest, continuously-dosed, placebo-controlled trials of a sleep medication ever conducted.

10 Sep 2012

Data from BioLineRx’s BL-7010 pre-clinical studies on celiac disease

BioLineRx, a biopharmaceutical development company, announced today that BL-7010, an orally available treatment for celiac disease, was found to be safe and well tolerated in pre-clinical studies conducted to date.

10 Sep 2012

Recent data from Silence Therapeutics’ Atu111 pre-clinical study on acute lung injury

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company is pleased to announce that recent data in pre-clinical models demonstrated the efficacy of Atu111 in acute lung injury.

10 Sep 2012

TauRx initiates LMTX Phase 3 trial in Pick's Disease

TauRx Therapeutics today announced the initiation of a global Phase 3 clinical trial in a type of Frontotemporal Dementia (FTD) also known as Pick's Disease. The announcement, which immediately follows The 8th International Conference on Frontotemporal Dementias, held 5-7 September in Manchester, England, underscores the need for new treatments for this form of dementia that is similar to Alzheimer's Disease, except that it tends to damage different areas of the brain and affects people as early as 40 years old.

10 Sep 2012

UC Irvine receives CIRM grant to advance stem cell-based treatments for AD, retinitis pigmentosa

Efforts to begin human clinical trials using stem cells to treat Alzheimer's disease and retinitis pigmentosa received a $37.3 million boost from the California Institute for Regenerative Medicine during its most recent round of funding on Sept. 5.

10 Sep 2012

Enrollment complete in DOUBle Phase 3 clinical trial of AzaSite Plus and DexaSite for blepharitis

InSite Vision Incorporated today announced that patient enrollment has been completed in the DOUBle Phase 3 clinical trial of AzaSite Plus (ISV-502) and DexaSite (ISV-305) for the treatment of blepharitis.

7 Sep 2012

Efficacy News and Research

Aethic, King's College London to develop first sunscreen based on mycosporine-like amino acids

HSS receives NFL grant for research into platelet-rich plasma and stem cells

Positive results from Santarus rifamycin SV MMX Phase III study on travelers' diarrhea

Minimally invasive esophagectomy viable alternative to open surgery

Dengue vaccine breakthrough

Pergamum initiates LL-37 Phase I/II trial in hard-to-heal venous leg ulcers

Cell Therapeutics launches Pixuvri in the European Union

Oxyphenbutazone can kill drug resistant TB

Palatin Technologies completes bremelanotide Phase 2B trial on female sexual dysfunction

Florida Hospital Tampa adopts FDA approved Trevo Pro Clot Retriever

HIV viruses with two genetic 'footprints' associated with greater vaccine efficacy

Islet Sciences licenses noninvasive technology from Winthrop for detecting Beta cell death

Increased use of powerful antipsychotic drugs to treat publicly insured children

Atox Bio AB103 for Necrotizing Soft Tissue Infections granted FDA Fast Track designation

Phase III data for Suvorexant, an investigational insomnia medicine, announced

Data from BioLineRx’s BL-7010 pre-clinical studies on celiac disease

Recent data from Silence Therapeutics’ Atu111 pre-clinical study on acute lung injury

TauRx initiates LMTX Phase 3 trial in Pick's Disease

UC Irvine receives CIRM grant to advance stem cell-based treatments for AD, retinitis pigmentosa

Enrollment complete in DOUBle Phase 3 clinical trial of AzaSite Plus and DexaSite for blepharitis

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News